| Literature DB >> 29034092 |
Sumire Sorano1, Tatsuya Fukami1, Maki Goto1, Sakiko Imaoka1, Miho Ando1, Yoko To1, Sumie Nakamura1, Hiroko Yamamoto1, Fuyuki Eguchi1, Hiroshi Tsujioka1.
Abstract
BACKGROUND: A placental polyp is an intrauterine polypoid mass or pedunculated mass occurring from residual trophoblastic tissue following abortion, cesarean section or vaginal delivery. Recently uterine preservation surgery represented by transcervical resection (TCR) has been performed for placental polyps. However TCR without intravascular intervention, including uterine artery embolization (UAE) may cause profound bleeding which necessitate emergency laparotomy.Entities:
Keywords: Placental polyp; Transcervical resection; Vascularity
Year: 2017 PMID: 29034092 PMCID: PMC5635338 DOI: 10.1016/j.amsu.2017.09.008
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Fig. 1Placental polyp.
Fig. 2Color Doppler ultrasound of blood flow within the polyp graded as high (2+) flow. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Profiles of the study patients.
Clinical profiles of patients with placental polyp.
| Age | G,P | Weeks | Mode | Interval | hCG | Bleeding | MRI | US doppler | vascularity | Intervention | Histology | Complication | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 33 | G4P2 | 7 | AA | 60 | – | + | – | NA | Weak | Observation | – | – |
| 2 | 25 | G3P0 | 14 | AA | 62 | <1.0 | + | – | NA | Weak | TCR | ○ | – |
| 3 | 32 | G4P3 | 5 | AA | 28 | 8 | + | 1+ | NA | Weak | TCR | ○ | – |
| 4 | 29 | G1P1 | 3 | TVD | 17 | 3.1 | Profound | 1+ | NA | Weak | TCR | – | – |
| 5 | 25 | G4P2 | full term | TVD | 56 | <1.0 | + | 2+ | 1+ | Strong | TCR | ○ | – |
| 6 | 33 | G5P3 | 40 | TVD | 40 | 3.9 | Profound | 2+ | 1+ | Strong | UAE + TCR | ○ | – |
| 7 | 41 | G1P1 | 37 | TVD | 27 | 10.2 | + | 2+ | 1+ | Strong | UAE + TCR | ○ | – |
| 8 | 39 | G1P1 | full term | TVD | 392 | – | – | 2+ | 2+ | Strong | UAE + TCR | – | – |
| 9 | 20 | G2P1 | 5 | SA | 66 | 15.5 | – | 2+ | 2+ | Strong | UAE + TCR | ○ | – |
| 10 | 30 | G1P1 | 38 | CS | 31 | <1.0 | Profound | 2+ | NA | Strong | TCR | – | |
| 11 | 31 | G2P1 | 34 | TVD | 21 | – | Profound | 2+ | NA | Strong | TCR | – | |
| 12 | 28 | G3P2 | 34 | TVD | 9 | – | Profound | NA | 2+ | Strong | UAE + TCR | ○ | – |
| 13 | 40 | G1P0 | 12 | SA | 33 | – | + | NA | 2+ | Strong | UAE + TCR | ○ | – |
| 14 | 34 | G3P3 | 39 | TVD | 19 | 9 | Profound | NA | 2+ | Strong | UAE + TCR | ○ | – |
| 15 | 28 | G7P2 | 9 | AA | 46 | 1.4 | Profound | 3+ | NA | Strong | UAE + TCR | ○ | – |
| 16 | 28 | G4P2 | 16 | SA | 33 | <1.0 | + | 3+ | 2+ | Strong | UAE + TCR | – | – |
| 17 | 34 | G2P1 | 40 | TVD | 21 | 625.1 | + | 3+ | 2+ | Strong | UAE + TCR | ○ | – |
SA: spontaneous abortion, AA: artificial abortion, TVD: transvaginal delivery, CS: cesarean section, NA: not available, TCR: transcervical resection, UAE: uterine artery embolization.
Major bleeding on the following day, transfusion, postoperative UAE.
Major bleeding during TCR, transfusion.
Clinical background of patients in weak vascularity group and strong vascularity group.
| Median (range) | All | Weak vascularity group | Strong vascularity group | P value |
|---|---|---|---|---|
| Age | 31 (20–41) | 30.5 (25–33) | 31 (20–41) | p = 0.624 |
| G | 3 (1–7) | 3.5 (1–4) | 2 (1–7) | p = 0.703 |
| P | 1 (0–3) | 1.5 (0–3) | 1 (0–3) | P = 1.000 |
| Weeks | 34 (5–10) | 10.5 (5–38) | 34 (5–40) | |
| Interval | 33 (9–392) | 44 (17–62) | 33 (9–392) | p = 0.871 |
| hCG | 3.5 (<1.0–625.1) | 3.1 (<1.0–8) | 3.9 (<1.0–625.1) | p = 0.600 |
| Intervention | ||||
| TCR | 6 | 3 | 3 | |
| UAE + TCR | 10 | 0 | 10 | |
The outcome of TCR without UAE in the weak vascularity group (n = 3) and the strong vascularity group (n = 3), and TCR with UAE in the strong vascularity group (n = 10).
| TCR without UAE | TCR with UAE | ||
|---|---|---|---|
| Weak vascularity group | Strong vascularity group | Strong vascularity group | |
| Successful resection | 3 (100%) | 3 (100%) | 10 (100%) |
| Complications | |||
| Bleeding | 0 | 2 (67%)* | 0 |
| Blood transfusion | 0 | 2 (67%) | 0 |
| Postoperative UAE | 0 | 1 (33%) | 0 |